Quantum Biopharma shares rise 1.49% premarket after Adaptimmune's deal with US WorldMeds.

Quantum Biopharma Ltd. rose 1.49% in premarket trading, with Adaptimmune's announcement of a definitive agreement with US WorldMeds to bring lete-cel to market and continue development of uza-cel in collaboration with Galapagos. The transaction includes a $55 million cash payment and up to $30 million in potential future payments upon achieving certain milestones. Adaptimmune will retain rights to its preclinical assets and restructure to support the transition of these therapies to US WorldMeds. Additionally, Sanofi's Sarclisa received approval in the EU for the treatment of newly diagnosed multiple myeloma, which may positively impact the biopharma sector.